12 completed, 9 terminated, 1 unknown, 1 withdrawn. 23 Phase 2, 11 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 23 | Completed 12, Terminated 9, Unknown 1, Withdrawn 1 |
| Phase 1 | 11 | Completed 8, Terminated 3 |
| Phase 3 | 1 | Terminated 1 |
Follow NewLink Genetics Corporation: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma Pembrolizumab, Nivolumab, Indoximod - Melanoma | Phase 2 | Terminated | NewLink Genetics Corporation | 21 | 2017-12-08 | 2022-09-27 |
| A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer CRLX101, Paclitaxel - Ovarian Cancer | Phase 1 / Phase 2 | Terminated | NewLink Genetics Corporation | 30 | 2015-07-01 | 2026-06-18 |
| Phase 1/2a Dose-Escalation Study of CRLX301 in Patients With Advanced Solid Tumors CRLX301 - Advanced Solid Tumor Malignancy | Phase 1 / Phase 2 | Terminated | NewLink Genetics Corporation | 42 | 2015-04-01 | 2020-06-09 |
| Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer mFOLFIRINOX, Algenpantucel-L Immunotherapy, SBRT - Pancreatic Cancer, Pancreatic Carcinoma Non-resectable | Phase 2 | Terminated | NewLink Genetics Corporation | 10 | 2015-04-01 | 2020-05-28 |
| Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer Nab-Paclitaxel, Gemcitabine, Indoximod - Metastatic Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | Completed | NewLink Genetics Corporation | 157 | 2014-08-01 | 2026-04-03 |
| CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC) CRLX101, Bevacizumab, Standard of Care (Investigator Choice) - Metastatic Renal Cell Carcinoma | Phase 2 | Completed | NewLink Genetics Corporation | 115 | 2014-07-01 | 2020-05-28 |
| Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma Indoximod, Ipilimumab, Nivolumab - Metastatic Melanoma, Stage III Melanoma | Phase 1 / Phase 2 | Completed | NewLink Genetics Corporation | 131 | 2014-07-01 | 2026-05-29 |
| Immunotherapy Study for Patients With Stage IV Melanoma HyperAcute®-Melanoma (HAM) Immunotherapy, Ipilimumab, Pembrolizumab - Stage IV Melanoma, Metastatic Melanoma | Phase 2 | Terminated | NewLink Genetics Corporation | 47 | 2014-06-01 | 2023-04-18 |
| Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors Indoximod, Temozolomide, Bevacizumab - Glioblastoma Multiforme, Glioma | Phase 1 / Phase 2 | Completed | NewLink Genetics Corporation | 160 | 2014-03-01 | 2024-03-27 |
| Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer Docetaxel, Placebo, Indoximod - Metastatic Breast Cancer | Phase 2 | Completed | NewLink Genetics Corporation | 169 | 2013-02-01 | 2020-05-28 |
| Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer Docetaxel, HyperAcute®-Lung Immunotherapy, Gemcitabine - Non-small Cell Lung Cancer, Progression of Non-small Cell Lung Cancer | Phase 2 / Phase 3 | Terminated | NewLink Genetics Corporation | 135 | 2013-02-01 | 2020-05-28 |
| A Phase 2 Study of CRLX101(NLG207) in Patients With Advanced Non-Small Cell Lung Cancer CRLX101, Best Supportive Care - Non-Small Cell Lung Cancer | Phase 2 | Completed | NewLink Genetics Corporation | 157 | 2011-06-01 | 2020-05-28 |
| Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients. IT-101 (12mg/m2/dose), IT-101 (15mg/m2/dose), 5% Dextrose (Placebo) - Cancer, Ovarian Cancer | Phase 2 | Withdrawn | NewLink Genetics Corporation | 2008-09-01 | 2020-06-12 | |
| A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma HyperAcute vaccine, Pegylated Interferon-Alpha 2b - Melanoma | Phase 2 | Unknown | Ochsner Health System | 30 | 2008-06-01 | 2011-01-13 |
| Low Dose Vaccine Study for Surgically Resected Pancreatic Cancer HyperAcute(R)-Pancreatic Cancer Vaccine - Pancreatic Cancer | Phase 2 | Terminated | NewLink Genetics Corporation | 9 | 2008-01-01 | 2020-05-28 |
| Vaccine Study for Surgically Resected Pancreatic Cancer HyperAcute(R)-Pancreatic Cancer Vaccine - Pancreatic Cancer | Phase 2 | Completed | NewLink Genetics Corporation | 73 | 2007-12-01 | 2020-05-28 |
| Vaccine Maintenance Treatment for Non-Small Cell Lung Cancer HyperAcute-Lung Cancer Vaccine - Carcinoma, Non-Small-Cell Lung | Phase 2 | Terminated | NewLink Genetics Corporation | 6 | 2007-01-01 | 2020-05-28 |
| Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer - Cancer, Solid Tumor | Phase 1 / Phase 2 | Completed | NewLink Genetics Corporation | 62 | 2006-05-01 | 2020-05-28 |
| Vaccine Treatment for Advanced Malignant Melanoma HyperAcute-Melanoma Vaccine - Malignant Melanoma | Phase 1 / Phase 2 | Completed | NewLink Genetics Corporation | 6 | 2006-03-01 | 2020-05-28 |
| Vaccine Treatment for Surgically Resected Pancreatic Cancer HyperAcute-Pancreatic Cancer Vaccine - Pancreatic Cancer | Phase 1 / Phase 2 | Completed | NewLink Genetics Corporation | 7 | 2005-11-01 | 2020-05-28 |
Showing 20 of 23. Sign in to see all of them.
Melanoma (6) · Pancreatic Neoplasms (6) · Carcinoma, Non-Small-Cell Lung (5) · Neoplasms (4) · Breast Neoplasms (3) · Ovarian Neoplasms (3) · Lung Neoplasms (2) · Prostatic Neoplasms (2) · Adenocarcinoma (1) · Adenocarcinoma of Lung (1) · Brain Neoplasms (1) · Carcinoma, Large Cell (1) · Carcinoma, Renal Cell (1) · Carcinoma, Squamous Cell (1) · Colonic Neoplasms (1)
1-methyltryptophan (5) · IT-101 (5) · Gemcitabine (3) · Nivolumab (3) · Paclitaxel (3) · pembrolizumab (3) · Bevacizumab (2) · Docetaxel (2) · Ipilimumab (2) · 130-nm albumin-bound paclitaxel (1) · 2-cyclohexylidenhydrazo-4-phenyl-thiazole (1) · ATF7IP protein, human (1) · Albumin-Bound Paclitaxel (1) · Algenpantucel-L (1) · Axitinib (1)
United States (22) · Poland (1) · Russia (1) · South Korea (1) · Ukraine (1)
Charles J. Link, M.D. (4) · Charles J. Link, Jr., M.D. (2) · NewLink Genetics (2) · Adam I Riker, MD (1) · Arun Rajan, M.D. (1) · Elizabeth Dees, MD (1) · Eugene Kennedy, MD (1) · Franco Muggia, MD (1) · Glenn Weiss, M.D. (1) · Jeffrey D. Neidhart, M.D. (1) · Jonathan S Berek, MD, MMS (1) · Mary Mulcahy, M.D. (1) · Ronald C. DeConti, M.D. (1) · Yun Yen, M.D., Ph.D. (1)
PMID 23229886, PMID 28950297, PMID 33151286, PMID 33390325, PMID 33594602, PMID 37534996